Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V, Glueck CJ, Lee K, Goldenberg N, Prince M, Kumar A, Goldenberg M, Anand I, Wang P. Jetty V, et al. Among authors: goldenberg n, goldenberg m. Vasc Health Risk Manag. 2017 Jul 6;13:247-253. doi: 10.2147/VHRM.S133690. eCollection 2017. Vasc Health Risk Manag. 2017. PMID: 28740397 Free PMC article.
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
Glueck CJ, Shah P, Goldenberg N, Prince M, Lee K, Jetty V, Kumar A, Goldenberg M, Wang P. Glueck CJ, et al. Among authors: goldenberg n, goldenberg m. Lipids Health Dis. 2016 Mar 12;15:55. doi: 10.1186/s12944-016-0227-2. Lipids Health Dis. 2016. PMID: 26968977 Free PMC article.
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.
Shah P, Glueck CJ, Goldenberg N, Min S, Mahida C, Schlam I, Rothschild M, Huda A, Wang P. Shah P, et al. Among authors: goldenberg n. Lipids Health Dis. 2017 Jan 23;16(1):19. doi: 10.1186/s12944-017-0416-7. Lipids Health Dis. 2017. PMID: 28115017 Free PMC article.
Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance.
Glueck CJ, Budhani SB, Masineni SS, Abuchaibe C, Khan N, Wang P, Goldenberg N. Glueck CJ, et al. Among authors: goldenberg n. Curr Med Res Opin. 2011 Sep;27(9):1683-90. doi: 10.1185/03007995.2011.598144. Epub 2011 Jul 6. Curr Med Res Opin. 2011. PMID: 21728907 Clinical Trial.
376 results